- Conditions
- Corneal Edema
- Interventions
- Netarsudil Ophthalmic
- Drug
- Lead sponsor
- Aerie Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 12
- States / cities
- Garden Grove, California • Laguna Hills, California • Edgewood, Kentucky + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–33
of 33
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Ocular Hypertension, Open Angle Glaucoma
- Interventions
- Netarsudil ophthalmic solution 0.02%, Netarsudil Ophthalmic Solution Vehicle
- Drug · Other
- Lead sponsor
- Aerie Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Bedminster, New Jersey
- Conditions
- Glaucoma
- Interventions
- Brimonidine Tartrate Ophthalmic 0.025%
- Drug
- Lead sponsor
- Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Glaucoma
- Interventions
- Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution
- Drug
- Lead sponsor
- Aerie Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 21
- States / cities
- Mission Hills, California • Newport Beach, California • Pasadena, California + 17 more
- Conditions
- Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
- Interventions
- Netarsudil Ophthalmic
- Drug
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Fuchs' Endothelial Dystrophy, Bullous Keratopathy
- Interventions
- Netarsudil, Placebo
- Drug
- Lead sponsor
- Cornea Research Foundation of America
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Open-angle Glaucoma, Ocular Hypertension
- Interventions
- PG324 Ophthalmic Solution 0.02%/0.005%, Netarsudil (AR-13324) ophthalmic solution 0.02%, Latanoprost ophthalmic solution 0.005%
- Drug
- Lead sponsor
- Aerie Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Bedminster, New Jersey
- Conditions
- Ocular Hypertension, Open Angle Glaucoma
- Interventions
- AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, Latanoprost ophthalmic solution 0.005%
- Drug
- Lead sponsor
- Aerie Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 22
- States / cities
- Artesia, California • Inglewood, California • Newport Beach, California + 19 more
- Conditions
- Primary Open Angle Glaucoma or Ocular Hypertension
- Interventions
- AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%, AR-13324 Ophthalmic Solution Placebo
- Drug
- Lead sponsor
- Aerie Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 40
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Azusa, California + 29 more